TrialNeuro-oncology2016

Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.

Wolfgang Wick et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.